Rethinking When to Start Long-Acting HIV Therapy

Real-world data from the OPERA cohort are challenging long-standing assumptions about when long-acting cabotegravir plus rilpivirine (CAB+RPV LA) can be initiated. Traditionally reserved for patients who are already virologically suppressed, this injectable regimen is now showing promising outcomes even among individuals with detectable viral loads at treatment initiation.
In a large dataset of more than 5000 patients, approximately 11% began therapy with viral loads above 50 copies/mL—outside current labeled indications. Despite this, many of these individuals achieved virologic suppression over time, with outcomes approaching those seen in patients who initiated treatment while already suppressed. These findings suggest that the pathway to suppression may not need to rely exclusively on oral therapy before transitioning to long-acting options.
This shift has important implications for clinical practice, particularly for patients who struggle with adherence to daily oral regimens. Factors such as stigma, pill fatigue, and inconsistent access to care can all contribute to suboptimal adherence, leaving some patients persistently viremic. Long-acting injectables may offer a viable alternative for these individuals, enabling providers to bypass barriers associated with daily dosing.
While these data are encouraging, they also raise important questions about patient selection, resistance risk, and optimal initiation strategies. Ongoing and future studies will be critical to defining how broadly this approach can be applied and under what conditions it is most effective.
Ultimately, these findings signal a potential paradigm shift—one in which long-acting therapies are not just a maintenance option, but a tool for achieving suppression in harder-to-treat populations.